| 发明名称 | Bacteriophage gene 3 protein compositions and use as amyloid binding agents | ||
| 摘要 | The invention relates to agents and to pharmaceutical compositions for reducing the formation of amyloid and/or for promoting the disaggregation of amyloid proteins. The compositions may also be used to detect amyloid. | ||
| 申请公布号 | US9493516(B2) | 申请公布日期 | 2016.11.15 |
| 申请号 | US201514797724 | 申请日期 | 2015.07.13 |
| 申请人 | PROCLARA BIOSCIENCES, INC. | 发明人 | Krishnan Rajaraman;Fisher Richard |
| 分类号 | A61P25/28;C12N15/01;C12P21/08;G01N33/68;C07K14/005;A61K38/16;A61K47/48;B82Y5/00;A61K51/10;C07K14/24;C07K16/00;C12N7/00;A61K38/00 | 主分类号 | A61P25/28 |
| 代理机构 | Finnegan, Henderson, Farabow, Garrett & Dunner, LLP | 代理人 | Finnegan, Henderson, Farabow, Garrett & Dunner, LLP |
| 主权项 | 1. A method of treating a subject for a disease or disorder associated with misfolded and/or aggregated amyloid beta, tau, α-synuclein, and/or prion protein, comprising administering to the subject an amyloid-binding polypeptide, wherein the polypeptide comprises at least one of: (a) a wild-type M13 g3p (SEQ ID NO:1), (b) an amyloid-binding fragment of wild-type M13 g3p, or (c) a mutant of (a) or (b) that is at least 95% identical to SEQ ID NO:1 or an amyloid-binding fragment of SEQ ID NO:1;and wherein the subject is not administered a filamentous bacteriophage. | ||
| 地址 | Cambridge MA US | ||